CLOSED
GET A PIECE OF SOLLIEVO PHARMACEUTICALS
When Minutes Matter
Show more
REASONS TO INVEST
TEAM
Robert Schultz, Ph.D. • President and CEO, Director
Read More
Peter Schineller • Commercial Strategic Advisor
With Sollievo, Peter works on average 1 hour per week and on an as-needed basis.
Read More
Steve King, BPharm • Business Development
Steve has been working with Sollievo for the past year
Read More
*Information provided by the American College of Emergency Physicians (source)
**Market statistics obtained from Transparency Market Research, “Acute Agitation and Aggression Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027”
***Information provided by the U.S. Food & Drug Administration and Premier Consulting (source, source)
In Emergency Healthcare Environments, Minutes Matter
Sollievo Pharmaceuticals is positioned to introduce one of the first new innovations in injectable benzodiazepines in decades with our debut product Proviza®. Aimed at addressing the skyrocketing injury rates among doctors and nurses when treating acutely agitated and violent patients, Proviza's rapid sedation has the potential to lower injury risk, improve workplace safety, and decrease associated hospital costs.
*Proviza® is currently in the prototype and development stage and is not currently not available for general use.
Benzodiazepines entered the market in the 1960s and have since been used to relax and sedate patients, yet little innovation towards the development of new intramuscular drugs or delivery methods to improve the time or variability in the onset of sedation has taken place since then. (source)
At Sollievo, we believe it's time for a change, and with our proprietary approach, frontline healthcare staff can maintain a safer environment with Proviza's fast intramuscular absorption, rapid sedation, and medium duration.
The Problem
Emergency Department Violence is a Growing Health Crisis
Violence against healthcare workers is a national health crisis, and according to firsthand reports, has continued to get worse. The American College of Emergency Physicians cites that 7 out of 10 emergency physicians report an increase in emergency department violence, with 80% of the pool surveyed citing an impact on patient care as a result. (source)
In addition to affecting patient care, violence in healthcare environments is costly for hospitals and harmful to frontline staff. ER nurses are injured at a rate 5x greater than other major industries, with 25% of psychiatric nurses experiencing disabling injuries from patient assaults at some point in their career.
Video clips from Royal Melbourne Hospital. (source, source, source)
Sollievo believes our solution can directly reduce this incidence of verbal and physical abuse that healthcare staff experience daily.
The Solution
Proviza Can Deliver Fast Sedation for Improved Healthcare Staff Safety
Sollievo is dedicated to improving workplace safety for our frontline ER healthcare professionals tasked with treating agitated and violent patients.
We believe our benzodiazepine product, Proviza, can deliver the fastest-acting intramuscular sedative in its class, with our research demonstrating a four-fold faster median time to peak concentration than the leading market solution (Lorazepam) and a 15-fold reduction in patient-to-patient variability.
Faster and consistent time to sedation of violent patients requires rapid and consistent drug delivery to the bloodstream.
*Proviza performance is anticipated based on previous preclinical and clinical studies of Avizafone, the active ingredient in Proviza.
Sollievo’s proprietary technology is key to turbocharging Proviza’s absorption from the injection site. Avizafone, the active ingredient in Proviza, is an extremely water-soluble drug. In contrast, the other intramuscular injectable benzodiazepines, are highly water-insoluble.
When injected into the muscle, these insoluble drugs prefer the comfort of the muscle and fat tissue at the injection site. Therefore, absorption from the muscle tissue is slow, leading to large patient variability in the blood levels and the onset of sedation.
Avizafone ignores the tissues surrounding the injection site, flying from the muscle into the more friendly bloodstream. There, it is rapidly converted by natural enzymes in the blood to Diazepam, an FDA-approved, efficacious, and safe benzodiazepine.
Another potential advantage of Proviza beyond fast sedation and predictable performance, is that it provides a useful duration of action lasting between 2-4-hours. In contrast, the duration of sedation for Lorazepam of 6-8 hours may interfere with timely diagnosis and treatment of the patient (source).
The Market
Sollievo Pharmaceuticals is Aiming to Disrupt a $1.2B Market
On average, current injectable sedatives take between 15-40 minutes for effects to act. Proviza’s target onset of action is less than 10 minutes, which we believe is a game-changing solution to reduce injury risk to the ER staff when treating violent patients.
Market statistics obtained from Transparency Market Research, “Acute Agitation and Aggression Treatment Market:
Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027”
Sollievo believes Proviza is the product to disrupt the sedative and antipsychotics markets. The global intramuscular acute agitation and aggression treatment market is estimated at $1.2B* and is predicted to have a CAGR of 5.1%.
*Market statistics obtained from Transparency Market Research
When presented with the drug's product profile, emergency physicians that we've spoken to have stated that, when available, they would prescribe Proviza in 60% of their cases.
Our Traction
Fast Track Examination Granted & Two Patents Pending
Since the start of 2022, six more states have passed or initiated legislation intended to protect healthcare workers from workplace violence. The awareness of the need for solutions to this epidemic is growing daily, validating the need for the unique solution that Proviza will be able to provide.
Currently, Sollievo Pharmaceuticals has two patent applications pending. The first is for the manufacturing process of the drug substance, with the second for a method of use to treat acute agitation and aggression.
Sollievo was granted fast-track examination of its method of use application by the USPTO for Proviza’s potential role in treating COVID-19 patients.
We additionally have engaged senior commercial and marketing advisors to facilitate the integration of the company’s regulatory, clinical, and commercial strategies to best position Proviza for launch and rapid market penetration.
Why Invest
Help Us Provide a Risk-Reducing Therapeutic Solution to our Frontline Healthcare Workers
We want Sollievo to be recognized as a bold leader overcoming the inertia of the pharma industry to find new solutions, while increasing the awareness of the plight of ER nurses, doctors, and other healthcare professionals.
In our view, the benefits of Proviza have the potential to disrupt the existing market, providing improved care for acutely agitated & aggressive patients. Help us support the medical community at large as we seek to provide a risk-reducing therapeutic solution to our frontline healthcare workers.
---
Caution: New Drug - Limited by Federal law to investigational use
ABOUT
HEADQUARTERS
32452 Spyglass Court
San Juan Capistrano, CA 92675
WEBSITE
View Site
TERMS
Sollievo Pharmaceuticals
Overview
PRICE PER SHARE
$2
DEADLINE
Dec. 17, 2022 at 7:59 AM UTC
VALUATION
$20M
FUNDING GOAL
$10K - $1.07M
Breakdown
MIN INVESTMENT
$400
MAX INVESTMENT
$120,000
MIN NUMBER OF SHARES OFFERED
5,000
MAX NUMBER OF SHARES OFFERED
535,000
OFFERING TYPE
Equity
SHARES OFFERED
Common Stock
Maximum Number of Shares Offered subject to adjustment for bonus shares
*Maximum number of shares offered subject to adjustment for bonus shares. See bonus info below.
Voting Rights of Securities Sold in this Offering
Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.
Investment Incentives & Bonuses*
Time-Based:
Super Early Bird Bonus
Invest within the first four weeks and receive 20% bonus shares.
Early Bird Bonus
Invest in weeks five & six and receive 15% bonus shares.
Amount-Based:
Company Bonus
Invest $500+ and receive 5% bonus shares.
Silver Bonus
Invest $1,000+ and receive 10% bonus shares.
Gold Bonus
Invest $5,000+ and receive 15% bonus shares.
Platinum Bonus
Invest $10,000+ and receive 20% bonus shares
*All perks occur when the offering is completed.
The 10% StartEngine OWNer's Bonus
Sollievo Pharmaceuticals, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $2.00 / share, you will receive 10 additional shares of Common Stock, meaning you'll own 110 shares of Common Stock for $200. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned bonus.
Irregular Use of Proceeds
ALL UPDATES
12.06.22
Sollievo's Campaign Closes in 10 days
Our StartEngine campaign is closing soon. Thank you to all of our current investors! If you haven’t yet invested, you can still do so until December 16th. Invest today and become part of the team that is actively targeting a reduction in the injury rate of the healthcare professionals faced with the dangerous job of treating violent patients daily in the ER.
Below are five excellent reasons to INVEST TODAY!
12.02.22
Sollievo's Current Offering is Closing Soon
11.28.22
Preventing Healthcare Violence
11.23.22
Sollievo's Keys to Success
11.22.22
Drug Shortages Impact Patient Care
Since the pandemic, shortages of the drugs used to put patients on respirators, treat epileptic seizures, and sedate agitated and violent patients continue to occur. Upon approval, Proviza will provide an excellent alternative to midazolam and lorazepam during times of high demand or when manufacturing issues limit their availability.
11.15.22
Notice of Material Change in Offering
[The following is an automated notice from the StartEngine team].
Hello! Recently, a change was made to the Sollievo Pharmaceuticals offering. Here's an excerpt describing the specifics of the change:
Issuer is extending campaign end date
When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.
11.08.22
Advocates Working to Stop ED Violence
I invite you to visit https://www.stopedviolence.org to read the most recent stories of assaults and attacks on emergency department personnel. This group advocates on behalf of the doctors and nurses who risk injury and abuse daily to ensure that medical care is available when we are most vulnerable.
Sollievo aims to provide the emergency department with an additional solution for patients exhibiting acute agitation and aggression. By delivering fast and consistent sedation, the time to calm a patient and return their attention to other patients will benefit us all.
Investing in Sollievo Pharmaceuticals is one way to show your support to those impacted by ED violence. #StopEDViolence
11.04.22
Investor Value Proposition
THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD-LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS
11.02.22
Treating acute aggression: Impact on the ER and other patients
11.01.22
Treating violent patients - Impact on the ER
REWARDS
10%
Stack Venture Club & Rewards!
Members get an extra 10% shares in addition to rewards below!
Venture Club
Venture Club Members earn 10% bonus shares on top of this and all eligible investments for an entire year. Not a member? Sign up at checkout ($275/year).
$500
Company Bonus
Invest $500+ and receive 5% bonus shares.
$1,000
Silver Bonus
Invest $1,000+ and receive 10% bonus shares.
$5,000
Gold Bonus
Invest $5,000+ and receive 15% bonus shares.
$10,000
Platinum Bonus
Invest $10,000+ and receive 20% bonus shares
JOIN THE DISCUSSION
0/2500
Mark Bell
3 years ago
There is definitely a need for better sedation delivery in the ED and within the hospital as well.. I’m curious, if your pitch is quick onset and water solubility of the medication, why are you charting/comparing Avizafone to the longer onset Benzodiazepines (like lorazepam and diazepam), and not Midazolam which has a rapid onset of just a couple and is also water soluble…? Seems like Midazolam would be the better comparison in market competition. Do you all have data comparing these two? Is the variability of peak concentration in Avizafone any lower than Midazolam? Or is the duration the only difference? Thanks, Mark
Show more
1
0
Furaha Bryant
3 years ago
Nice pitch deck! It'll erase all investor-doubt!
3
0
Richard Koch
3 years ago
Is the vision for use in a hospital setting only or do you foresee Paramedics in the field administering to a combative arrestee or patient? Any legal concerns should patients be administered the compound involuntary?
Show more
1
0
Viral Kothary
3 years ago
These are much needed agents in the ED for psych patients, and other acutely agitated patients. Is the intent for avizafone to be used in conjunction with an antipsychotic (haloperidol, ziprazidone, etc) plus and antihistamine (diphenhydramine) which is standard in most acute care hospitals. Also, since avizafone is a prodrug that converts into diazepam, will there be long term issues in evaluating conversion to maintenance therapy? Although it has a faster onset and duration compared to other benzos (lorazepam being the most commonly used), the half life of diazepam is significantly longer than any other benzo. Some effects can still be seen for days after the acute dose is given. Is Sollievo taking this into consideration with your trials? If so, what is being seen with conversion to maintenance therapy? Thanks.
Show more
3
0
Richard Koch
3 years ago
Is the vision for use in a hospital setting or do you foresee Paramedics in the field sticking a combative arrestee or patient? Any legal concerns should "involuntary" recipients who might decide to show their disapproval with a slick lawyer?
Show more
1
0
Mohammad Karim
3 years ago
Since Avizafone is already approved by FDA, do you have to conduct Safety Trial for Proviza?
1
0
Michael Brody
3 years ago
There is a new short-acting benzodiazepine Remimazolam. It’s already FDA approved. How would your product have an advantage?
Show more
3
0
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
FAQS
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000 are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, they are limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancellation period. Once the four-hour window has passed, it is up to each company to set their own cancellation policy. You may find the company’s cancellation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to be sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
Aaron Samuel
3 years ago
I’m a medical student Risperidone is indicated in violent patients what does your medication do?
2
0